Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 13/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354698 | 1.00 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139SCN9A | |
| SCHEMBL20180478 | 1.00 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139SCN9A | |
| SCHEMBL10115935 | 0.84 | TRPV4 (0.46) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL14612275 | 0.84 | TRPV4 (0.46) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL469196 | 0.84 | TRPV4 (0.46) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL21346242 | 0.83 | TRPV3 (0.43) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL31477305 | 0.83 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL19831923 | 0.81 | TRPV4 (0.43) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL1495491 | 0.81 | SCN9A (0.46) | TRPV4TRPV3P2RX7SCN9A | |
| SCHEMBL347477 | 0.80 | TRPV4 (0.48) | TRPV4TRPV3P2RX7GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860178-A2 | P2X3 receptor antagonists for treatment of pain | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2358371-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2015-02-11 | — | — | EP | disclosed |